FUJIFILM Holdings

CSR activity report

Health

Create a healthy society through the process of prevention, diagnosis and treatment in healthcare.

[SPECIAL CONTENT] Fighting Against COVID-19

Targets for FY2030 Major activities of FY2020 Self-
evalution
Develop and disseminate new treatments based on regenerative medicine and cell therapy
  • Establish a new process development and manufacturing facility for viral vectors and advanced therapies at FUJIFILM Diosynth Biotechnologies in the U.K.
  • Succeeded in propagating the human norovirus using human iPSC-derived intestinal epithelial cells
  • Participated in the Massachusetts Center for Advanced Biological Innovation and Manufacturing, PBLLC, an industry-academia joint research and development consortium in the fi eld of state-of-the-art treatment
Targets for FY2030 Major activities of FY2020 Self-
evalution

(1) Reducing burden on medical professionals by utilizing IT

  • Launched pulmonary nodule detection and analysis functions for SYNAPSE SAI viewer, an AI platform, in Japan
  • Launched SYNAPSE Radiotherapy, a radiotherapy planning support software that utilizes AI, in Japan
  • FUJIFILM Healthcare Corporation newly joined the Fujifilm Group, adding CT, MRI and other devices to the Group’s medical equipment lineup, launching higher value-added solutions centered on medical IT globally
  • Manufactured drug substance for COVID-19 vaccine candidates and provided contract manufacturing for COVID-19 vaccine formulation
  • Launched COVID-19 gene detection reagents, gene detection kits and antigen test kits
  • Opened a cancer-focused screening center in India
  • Expanded biopharmaceutical manufacturing facilities at the Denmark facility
(2) Development and dissemination of infectious disease diagnostic system to contribute to global health
(3) Offering technical diagnosis training and spreading effective health practices to emerging countries
Targets for FY2030 Major activities of FY2020 Self-
evalution
Reduce the physical burden through widespread and expanded use of medical diagnostic systems
  • Launched pulmonary nodule detection and analysis functions for SYNAPSE SAI viewer, an AI platform, in Japan
  • Launched SYNAPSE Radiotherapy, a radiotherapy planning support software that utilizes AI, in Japan
  • FUJIFILM Healthcare Corporation newly joined the Fujifilm Group, adding CT, MRI and other devices to the Group’s medical equipment lineup, launching higher value-added solutions centered on medical IT globally
  • Manufactured drug substance for COVID-19 vaccine candidates and provided contract manufacturing for COVID-19 vaccine formulation
  • Launched COVID-19 gene detection reagents, gene detection kits and antigen test kits
  • Opened a cancer-focused screening center in India
  • Expanded biopharmaceutical manufacturing facilities at the Denmark facility
Targets for FY2030 Major activities of FY2020 Self-
evalution
(1) Promote to prolong healthy lives
  • Newly developed nanotetrahydropiperine, an ingredient that improves skin elasticity
  • Clearly determined the mechanism by which melanin, which causes age spots, stays in the stratum corneum
(2) Promote support for women’s empowerment
Targets for FY2030 Major activities of FY2020 Self-
evalution
Promote management of health and productivity to maintain employees’ vitality
  • Held health management e-learning programs for Fujifilm Group employees in Japan
  • Internally published the Declaration of Commitment to Health by Fujifilm Group officers in Japan
  • Incorporated smoking ban during work hours into work regulations

We aim to be proactive in developing technologies that will enable the use of liposomes as a drug delivery system*1, utilizing our unique expertise and focusing on areas where medical needs are unmet, such as cancer, central nervous system diseases and infectious diseases. The scope of our healthcare business is wide and includes development of antibody drugs and vaccines in the currently expanding biopharmaceutical market, contract manufacturing of small-molecule drugs and regenerative medicine and cell cultures for drug development. We are also proceeding with the production of anti-aging cosmetics and food supplements with functional claims and the use of AI technology in medical IT and to support diagnoses. We are working to set separate KPIs and targets for each issue and in each area relating to employee wellness.

  • *1 Drug delivery system: Technology to deliver the required amount of a drug to a specific destination at the correct time. Preparing pharmaceuticals in the form of liposomes allows the pharmaceutical to be delivered selectively to the tumor, and this can be expected to improve pharmacological efficacy and suppress adverse effects.
  • * This page contains some excerpts from the Sustainability Report.

Initiatives for Occupational Health and Safety (Fujifilm)

Work Safety/Health Promotion (FUJIFILM Business Innovation)